Comparative Pharmacology
Head-to-head clinical analysis: PREVACID NAPRAPAC 500 COPACKAGED versus YOSPRALA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREVACID NAPRAPAC 500 COPACKAGED versus YOSPRALA.
PREVACID NAPRAPAC 500 (COPACKAGED) vs YOSPRALA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lansoprazole inhibits gastric acid secretion by irreversibly binding to the H+/K+ ATPase (proton pump) in gastric parietal cells. Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Yosprala is a combination of aspirin (a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 and cyclooxygenase-2, thereby reducing thromboxane A2 synthesis and platelet aggregation) and omeprazole (a proton pump inhibitor that inhibits gastric acid secretion by binding to the H+/K+ ATPase enzyme in gastric parietal cells).
One tablet of naproxen 500 mg and one capsule of lansoprazole 15 mg taken together orally once daily. Naproxen component: 500 mg orally twice daily. Lansoprazole component: 15 mg orally once daily.
YOSPRALA (esomeprazole magnesium and naproxen) is available as delayed-release tablets containing 375 mg naproxen/20 mg esomeprazole or 500 mg naproxen/20 mg esomeprazole. The typical adult dose is one tablet twice daily, swallowed whole with liquid, at least 30 minutes before meals.
None Documented
None Documented
Naproxen: 12–17 hours (mean ~14 h), prolonged with renal impairment. Esomeprazole: 1–1.5 hours (increase to 2–3 h with CYP2C19 poor metabolizers or hepatic impairment).
Naproxen: terminal elimination half-life is approximately 14 hours (range 12–17 hours), allowing twice-daily dosing. Esomeprazole: terminal half-life is approximately 1.2–1.5 hours after single dose, increasing to ~1.5–2.5 hours with repeated dosing due to saturation of CYP2C19. Clinical context: naproxen's half-life supports sustained analgesic/anti-inflammatory effect; esomeprazole's shorter half-life requires daily dosing for acid suppression.
Naproxen: 95% renal (primarily as unchanged drug and metabolites, including 6-O-desmethyl naproxen), <5% biliary/fecal. Esomeprazole: 80% renal (as metabolites, primarily hydroxyesomeprazole and desmethyl-esomeprazole, with ~1% unchanged), 20% fecal (via bile).
YOSPRALA (esomeprazole and naproxen) is a fixed-dose combination. Naproxen is primarily excreted in urine as unchanged drug (approximately 60%) and as glucuronide conjugates (approximately 30%). Esomeprazole is extensively metabolized; less than 1% of the dose is excreted unchanged in urine. Biliary/fecal elimination accounts for the remainder via metabolites.
Category C
Category C
Proton Pump Inhibitor/NSAID Combination
Proton Pump Inhibitor